Several small molecules, such AZD4547 and PD173073, targeting the FGFR1 tyrosine kinase are now in clinical trials for the treatment of patients with squamous cell lung cancer and other solid malignant tumors [13, 34]. Here, FGFR1 is linked to squamous cell lung carcinoma.